Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies
AI-extracted · unverified · confirm at source
Systematic review of 12 clinical studies (163 completed participants): zero serious adverse events in controlled settings; all reported fatalities occurred in uncontrolled settings without medical oversight.
Dosing: Ibogaine HCl 20–800 mg or 8–12 mg/kg; noribogaine HCl 3–180 mg; one study used 1800 mg encapsulated extract (75% purity) — all oral, across 12 reviewed clinical studies (oral)
Safety data present: QTC
Contraindications: Administration in uncontrolled settings without medical supervision, Absence of cardiac monitoring equipment (ECG/telemetry), Absence of pre-treatment medical screening protocols, Pre-existing cardiovascular disease or abnormalities, Pre-existing hepatic disease (e.g., chronic hepatitis C), Axis I psychotic disorders (schizophrenia, bipolar disorder, psychotic spectrum), Active suicidality or homicidality, Dissociative disorders or high risk of developing severe mental illness, Personal or family history of bipolar or psychotic disorders, Concomitant use of psychotropic medications without adequate discontinuation, Concurrent use of other substances of abuse, Unknown-purity or uncharacterised ibogaine preparations (root bark, unverified extracts), Nutritional deficiencies (risk factor for QT prolongation)